PB-201
- Generic Name
- PB-201
Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy
Phase 3
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 546
- Registration Number
- NCT05326490
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 672
- Registration Number
- NCT05102149
- Locations
- 🇨🇳
Shiyan Renmin Hospital, Shiyan, Hubei, China
🇨🇳Lu'an People's Hospital, Lu'an, Anhui, China
🇨🇳Lanzhou University Second Hospital, Lanzhou, Gansu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath